Centessa Pharmaceuticals Plc Financials
This page shows Centessa Pharmaceuticals Plc (CNTA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Centessa Pharmaceuticals Plc has an operating margin of -1384.6%, meaning the company retains $-1385 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Centessa Pharmaceuticals Plc carries a low D/E ratio of 0.21, meaning only $0.21 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.57, Centessa Pharmaceuticals Plc holds $8.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Centessa Pharmaceuticals Plc generated -$193.8M in operating cash flow, capex of $371K consumed most of it, leaving -$194.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Centessa Pharmaceuticals Plc generates a -37.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -58.7% the prior year.
Centessa Pharmaceuticals Plc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Centessa Pharmaceuticals Plc generates $0.98 in operating cash flow (-$193.8M OCF vs -$197.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Centessa Pharmaceuticals Plc earns $-18.1 in operating income for every $1 of interest expense (-$207.7M vs $11.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Centessa Pharmaceuticals Plc generated $15.0M in revenue in fiscal year 2025.
Centessa Pharmaceuticals Plc's EBITDA was -$206.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.3% from the prior year.
Centessa Pharmaceuticals Plc reported -$197.5M in net income in fiscal year 2025. This represents an increase of 16.2% from the prior year.
Centessa Pharmaceuticals Plc earned $-1.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 29.1% from the prior year.
Cash & Balance Sheet
Centessa Pharmaceuticals Plc generated -$194.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 36.7% from the prior year.
Centessa Pharmaceuticals Plc held $61.3M in cash against $110.1M in long-term debt as of fiscal year 2025.
Centessa Pharmaceuticals Plc had 155M shares outstanding in fiscal year 2025. This represents an increase of 16.5% from the prior year.
Margins & Returns
Centessa Pharmaceuticals Plc's operating margin was -1384.6% in fiscal year 2025, reflecting core business profitability.
Centessa Pharmaceuticals Plc's net profit margin was -1316.9% in fiscal year 2025, showing the share of revenue converted to profit.
Centessa Pharmaceuticals Plc's ROE was -37.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 21.2 percentage points from the prior year.
Capital Allocation
Centessa Pharmaceuticals Plc invested $172.2M in research and development in fiscal year 2025. This represents an increase of 14.6% from the prior year.
Centessa Pharmaceuticals Plc invested $371K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 991.2% from the prior year.
CNTA Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0-100.0% | $15.0M | N/A | $0 | $0 | $0 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $41.6M-2.8% | $42.7M+27.8% | $33.4M | N/A | $33.9M+3.3% | $32.8M+44.9% | $22.7M | N/A |
| SG&A Expenses | $12.2M+2.6% | $11.9M-3.4% | $12.3M | N/A | $12.5M+12.0% | $11.2M-16.9% | $13.4M | N/A |
| Operating Income | -$53.8M+1.6% | -$54.7M-77.6% | -$30.8M | N/A | -$46.4M-5.5% | -$44.0M-21.9% | -$36.1M | N/A |
| Interest Expense | $2.9M+0.2% | $2.9M+0.2% | $2.9M | N/A | $2.6M+1.3% | $2.5M-0.2% | $2.5M | N/A |
| Income Tax | $166K-78.7% | $778K-44.3% | $1.4M | N/A | $608K-13.8% | $705K+46.6% | $481K | N/A |
| Net Income | -$54.9M-9.0% | -$50.3M-92.6% | -$26.1M | N/A | -$42.6M+2.9% | -$43.8M-15.2% | -$38.0M | N/A |
| EPS (Diluted) | $-0.41-7.9% | $-0.38-90.0% | $-0.20 | N/A | $-0.37+7.5% | $-0.40-5.3% | $-0.38 | N/A |
CNTA Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $448.3M-8.9% | $492.1M-6.8% | $527.8M-8.5% | $576.8M-5.4% | $609.7M+52.9% | $398.8M+21.5% | $328.2M-8.9% | $360.2M |
| Current Assets | $307.7M+2.4% | $300.4M-13.6% | $347.7M-35.2% | $536.4M-5.6% | $568.4M+59.9% | $355.5M+25.0% | $284.5M-9.7% | $315.1M |
| Cash & Equivalents | $50.8M+14.8% | $44.2M-57.9% | $105.2M-72.6% | $383.2M-3.0% | $395.0M+210.1% | $127.4M+7.7% | $118.2M-7.7% | $128.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $146.7M-0.3% | $147.2M+4.0% | $141.6M-19.2% | $175.3M+58.5% | $110.6M-1.2% | $111.9M-1.0% | $113.0M-8.9% | $124.0M |
| Current Liabilities | $29.1M-1.9% | $29.7M+22.7% | $24.2M-58.3% | $58.0M+119.6% | $26.4M-1.3% | $26.8M-2.5% | $27.4M-30.3% | $39.4M |
| Long-Term Debt | $109.8M+0.2% | $109.5M+0.3% | $109.3M+0.3% | $108.9M+43.9% | $75.7M-1.0% | $76.5M-0.4% | $76.8M+1.5% | $75.7M |
| Total Equity | $301.6M-12.6% | $344.9M-10.7% | $386.2M-3.8% | $401.5M-19.6% | $499.1M+73.9% | $287.0M+33.4% | $215.2M-8.9% | $236.2M |
| Retained Earnings | -$1.1B-5.2% | -$1.1B-5.0% | -$1.0B-2.6% | -$988.7M-12.7% | -$877.4M-5.1% | -$834.8M-5.5% | -$791.0M-5.1% | -$752.9M |
CNTA Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$58.3M-159.7% | -$22.5M+60.8% | -$57.2M-33.8% | -$42.8M-100.1% | -$21.4M+47.3% | -$40.6M-8.8% | -$37.3M-20.1% | -$31.1M |
| Capital Expenditures | $234K | N/A | N/A | $0-100.0% | $34K | $0 | $0-100.0% | $28K |
| Free Cash Flow | -$58.5M | N/A | N/A | -$42.8M-99.8% | -$21.4M+47.2% | -$40.6M-8.8% | -$37.3M-20.0% | -$31.1M |
| Investing Cash Flow | $61.9M+255.0% | -$40.0M+82.0% | -$222.4M-989.6% | $25.0M-44.4% | $45.0M+181.1% | -$55.5M-430.9% | $16.8M+191.7% | -$18.3M |
| Financing Cash Flow | $3.4M+114.1% | $1.6M-48.0% | $3.1M+4.2% | $3.0M-98.8% | $246.0M+133.6% | $105.3M+903.7% | $10.5M+65.0% | $6.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CNTA Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -205.2% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | -174.2% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -18.2%-3.6pp | -14.6%-7.8pp | -6.8% | N/A | -8.5%+6.7pp | -15.3%+2.4pp | -17.7% | N/A |
| Return on Assets | -12.2%-2.0pp | -10.2%-5.3pp | -5.0% | N/A | -7.0%+4.0pp | -11.0%+0.6pp | -11.6% | N/A |
| Current Ratio | 10.56+0.4 | 10.12-4.3 | 14.37+5.1 | 9.25-12.3 | 21.52+8.2 | 13.29+2.9 | 10.37+2.4 | 8.00 |
| Debt-to-Equity | 0.36+0.0 | 0.32+0.0 | 0.28+0.0 | 0.27+0.1 | 0.15-0.1 | 0.27-0.1 | 0.36+0.0 | 0.32 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Centessa Pharmaceuticals Plc's annual revenue?
Centessa Pharmaceuticals Plc (CNTA) reported $15.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Centessa Pharmaceuticals Plc profitable?
No, Centessa Pharmaceuticals Plc (CNTA) reported a net income of -$197.5M in fiscal year 2025, with a net profit margin of -1316.9%.
What is Centessa Pharmaceuticals Plc's EBITDA?
Centessa Pharmaceuticals Plc (CNTA) had EBITDA of -$206.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Centessa Pharmaceuticals Plc have?
As of fiscal year 2025, Centessa Pharmaceuticals Plc (CNTA) had $61.3M in cash and equivalents against $110.1M in long-term debt.
What is Centessa Pharmaceuticals Plc's operating margin?
Centessa Pharmaceuticals Plc (CNTA) had an operating margin of -1384.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Centessa Pharmaceuticals Plc's net profit margin?
Centessa Pharmaceuticals Plc (CNTA) had a net profit margin of -1316.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Centessa Pharmaceuticals Plc's return on equity (ROE)?
Centessa Pharmaceuticals Plc (CNTA) has a return on equity of -37.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Centessa Pharmaceuticals Plc's free cash flow?
Centessa Pharmaceuticals Plc (CNTA) generated -$194.2M in free cash flow during fiscal year 2025. This represents a -36.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Centessa Pharmaceuticals Plc's operating cash flow?
Centessa Pharmaceuticals Plc (CNTA) generated -$193.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Centessa Pharmaceuticals Plc's total assets?
Centessa Pharmaceuticals Plc (CNTA) had $687.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Centessa Pharmaceuticals Plc's capital expenditures?
Centessa Pharmaceuticals Plc (CNTA) invested $371K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Centessa Pharmaceuticals Plc spend on research and development?
Centessa Pharmaceuticals Plc (CNTA) invested $172.2M in research and development during fiscal year 2025.
What is Centessa Pharmaceuticals Plc's current ratio?
Centessa Pharmaceuticals Plc (CNTA) had a current ratio of 8.57 as of fiscal year 2025, which is generally considered healthy.
What is Centessa Pharmaceuticals Plc's debt-to-equity ratio?
Centessa Pharmaceuticals Plc (CNTA) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Centessa Pharmaceuticals Plc's return on assets (ROA)?
Centessa Pharmaceuticals Plc (CNTA) had a return on assets of -28.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Centessa Pharmaceuticals Plc's cash runway?
Based on fiscal year 2025 data, Centessa Pharmaceuticals Plc (CNTA) had $61.3M in cash against an annual operating cash burn of $193.8M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Centessa Pharmaceuticals Plc's Piotroski F-Score?
Centessa Pharmaceuticals Plc (CNTA) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Centessa Pharmaceuticals Plc's earnings high quality?
Centessa Pharmaceuticals Plc (CNTA) has an earnings quality ratio of 0.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Centessa Pharmaceuticals Plc cover its interest payments?
Centessa Pharmaceuticals Plc (CNTA) has an interest coverage ratio of -18.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Centessa Pharmaceuticals Plc?
Centessa Pharmaceuticals Plc (CNTA) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.